{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:20:49Z","timestamp":1790659249791,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Key Program for Science & Technology of Henan Province","award":["252102310150"],"award-info":[{"award-number":["252102310150"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40261-025-01484-1","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T06:45:52Z","timestamp":1758609952000},"page":"837-845","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Resmetirom: The First FDA-Approved Drug for Metabolic Dysfunction-Associated Steatohepatitis (MASH) with a Perspective on Precision Medicine"],"prefix":"10.1007","volume":"45","author":[{"given":"Fengshuo","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yicong","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengran","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3230-3148","authenticated-orcid":false,"given":"Yun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"issue":"6","key":"1484_CR1","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542\u201356. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003.","journal-title":"J Hepatol"},{"issue":"9","key":"1484_CR2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/s2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851\u201361. https:\/\/doi.org\/10.1016\/s2468-1253(22)00165-0.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"1484_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11\u201320. https:\/\/doi.org\/10.1038\/nrgastro.2017.109.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1484_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065843","author":"X Wang","year":"2023","unstructured":"Wang X, Wang L, Geng L, Tanaka N, Ye B. Resmetirom ameliorates NASH-model mice by suppressing STAT3 and NF-\u03baB signaling pathways in an RGS5-dependent manner. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24065843.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"1484_CR5","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","volume":"184","author":"R Loomba","year":"2021","unstructured":"Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184(10):2537\u201364. https:\/\/doi.org\/10.1016\/j.cell.2021.04.015.","journal-title":"Cell"},{"issue":"3","key":"1484_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.103910","volume":"29","author":"S Wei","year":"2024","unstructured":"Wei S, Wang L, Evans PC, Xu S. NAFLD and NASH: etiology, targets and emerging therapies. Drug Discov Today. 2024;29(3):103910. https:\/\/doi.org\/10.1016\/j.drudis.2024.103910.","journal-title":"Drug Discov Today"},{"issue":"5","key":"1484_CR7","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrendo.2018.10","volume":"14","author":"RA Sinha","year":"2018","unstructured":"Sinha RA, Singh BK, Yen PM. Direct effects of thyroid hormones on hepatic lipid metabolism. Nat Rev Endocrinol. 2018;14(5):259\u201369. https:\/\/doi.org\/10.1038\/nrendo.2018.10.","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"1484_CR8","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1089\/thy.2019.0763","volume":"30","author":"S Minakhina","year":"2020","unstructured":"Minakhina S, Bansal S, Zhang A, et al. A direct comparison of thyroid hormone receptor protein levels in mice provides unexpected insights into thyroid hormone action. Thyroid. 2020;30(8):1193\u2013204. https:\/\/doi.org\/10.1089\/thy.2019.0763.","journal-title":"Thyroid"},{"issue":"2","key":"1484_CR9","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1073\/pnas.0705286104","volume":"105","author":"A Berkenstam","year":"2008","unstructured":"Berkenstam A, Kristensen J, Mellstrom K, et al. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc Natl Acad Sci U S A. 2008;105(2):663\u20137. https:\/\/doi.org\/10.1073\/pnas.0705286104.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"1484_CR10","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/s1074-5521(98)90168-5","volume":"5","author":"G Chiellini","year":"1998","unstructured":"Chiellini G, Apriletti JW, Yoshihara HA, Baxter JD, Ribeiro RC, Scanlan TS. A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor. Chem Biol. 1998;5(6):299\u2013306. https:\/\/doi.org\/10.1016\/s1074-5521(98)90168-5.","journal-title":"Chem Biol"},{"issue":"6","key":"1484_CR11","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S2213-8587(14)70006-3","volume":"2","author":"B Sjouke","year":"2014","unstructured":"Sjouke B, Langslet G, Ceska R, et al. Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study. Lancet Diabetes Endocrinol. 2014;2(6):455\u201363. https:\/\/doi.org\/10.1016\/S2213-8587(14)70006-3.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"1484_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1517\/14728222.2016.1090429","volume":"20","author":"J Lammel Lindemann","year":"2016","unstructured":"Lammel Lindemann J, Webb P. Sobetirome: the past, present and questions about the future. Expert Opin Ther Targets. 2016;20(2):145\u20139. https:\/\/doi.org\/10.1517\/14728222.2016.1090429.","journal-title":"Expert Opin Ther Targets"},{"key":"1484_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1127517","volume":"13","author":"A Caddeo","year":"2023","unstructured":"Caddeo A, Serra M, Sedda F, et al. Potential use of TG68 - a novel thyromimetic - for the treatment of non-alcoholic fatty liver (NAFLD)-associated hepatocarcinogenesis. Front Oncol. 2023;13:1127517. https:\/\/doi.org\/10.3389\/fonc.2023.1127517.\u00a0","journal-title":"Front Oncol"},{"key":"1484_CR14","unstructured":"FDA Approved Drug Products: REZDIFFRA (resmetirom) tablets, for oral use. Secondary FDA Approved Drug Products: REZDIFFRA (resmetirom) tablets, for oral use. https:\/\/nctr-crs.fda.gov\/fdalabel\/services\/spl\/set-ids\/e67ea09f-a840-439c-86c8-f98585f978b2\/spl-doc?hl=resmetirom"},{"issue":"5","key":"1484_CR15","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1021\/acs.jmedchem.2c01669","volume":"66","author":"L Hu","year":"2023","unstructured":"Hu L, Gu Y, Liang J, et al. Discovery of highly potent and selective thyroid hormone receptor \u03b2 agonists for the treatment of nonalcoholic steatohepatitis. J Med Chem. 2023;66(5):3284\u2013300. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c01669.","journal-title":"J Med Chem"},{"issue":"10","key":"1484_CR16","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1021\/jm4019299","volume":"57","author":"MJ Kelly","year":"2014","unstructured":"Kelly MJ, Pietranico-Cole S, Larigan JD, et al. Discovery of 2-[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a highly selective thyroid hormone receptor \u03b2 agonist in clinical trials for the treatment of dyslipidemia. J Med Chem. 2014;57(10):3912\u201323. https:\/\/doi.org\/10.1021\/jm4019299.\u00a0","journal-title":"J Med Chem"},{"issue":"4","key":"1484_CR17","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1210\/en.2003-0973","volume":"145","author":"GJ Grover","year":"2004","unstructured":"Grover GJ, Egan DM, Sleph PG, et al. Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3\u2019-triiodo-L-thyronine. Endocrinology. 2004;145(4):1656\u201361. https:\/\/doi.org\/10.1210\/en.2003-0973.\u00a0","journal-title":"Endocrinology"},{"issue":"1","key":"1484_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41575-024-00991-4","volume":"22","author":"RA Sinha","year":"2025","unstructured":"Sinha RA, Bruinstroop E, Yen PM. Actions of thyroid hormones and thyromimetics on the liver. Nat Rev Gastroenterol Hepatol. 2025;22(1):9\u201322. https:\/\/doi.org\/10.1038\/s41575-024-00991-4.\u00a0","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"1484_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/HC9.0000000000000596","volume":"9","author":"L Soares De Oliveira","year":"2025","unstructured":"Soares De Oliveira L, Ritter MJ. Thyroid hormone and the Liver. Hepatol Commun. 2025;9(1):10. https:\/\/doi.org\/10.1097\/HC9.0000000000000596.\u00a0","journal-title":"Hepatol Commun"},{"issue":"22","key":"1484_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232213714","volume":"23","author":"GS H\u00f6nes","year":"2022","unstructured":"H\u00f6nes GS, Sivakumar RG, Hoppe C, K\u00f6nig J, F\u00fchrer D, Moeller LC. Cell-specific transport and thyroid hormone receptor isoform selectivity account for hepatocyte-targeted thyromimetic action of MGL-3196. Int J Mol Sci. 2022;23(22):13714. https:\/\/doi.org\/10.3390\/ijms232213714.","journal-title":"Int J Mol Sci"},{"key":"1484_CR21","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnz008","author":"S Groeneweg","year":"2020","unstructured":"Groeneweg S, van Geest FS, Peeters RP, Heuer H, Visser WE. Thyroid hormone transporters. Endocr Rev. 2020. https:\/\/doi.org\/10.1210\/endrev\/bnz008.","journal-title":"Endocr Rev"},{"key":"1484_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101266","volume":"53","author":"E Bruinstroop","year":"2021","unstructured":"Bruinstroop E, Zhou J, Tripathi M, et al. Early induction of hepatic deiodinase type 1 inhibits hepatosteatosis during NAFLD progression. Mol Metab. 2021;53:101266. https:\/\/doi.org\/10.1016\/j.molmet.2021.101266.\u00a0","journal-title":"Mol Metab"},{"issue":"10","key":"1484_CR23","doi-asserted-by":"publisher","first-page":"5031","DOI":"10.1021\/acs.jmedchem.9b01701","volume":"63","author":"FA Romero","year":"2020","unstructured":"Romero FA, Jones CT, Xu Y, Fenaux M, Halcomb RL. The race to bash NASH: emerging targets and drug development in a complex liver disease. J Med Chem. 2020;63(10):5031\u201373. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01701.\u00a0","journal-title":"J Med Chem"},{"issue":"8","key":"1484_CR24","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1080\/15548627.2015.1061849","volume":"11","author":"RA Sinha","year":"2015","unstructured":"Sinha RA, Singh BK, Zhou J, et al. Thyroid hormone induction of mitochondrial activity is coupled to mitophagy via ROS-AMPK-ULK1 signaling. Autophagy. 2015;11(8):1341\u201357. https:\/\/doi.org\/10.1080\/15548627.2015.1061849.","journal-title":"Autophagy"},{"issue":"9","key":"1484_CR25","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1089\/thy.2018.0664","volume":"29","author":"RA Sinha","year":"2019","unstructured":"Sinha RA, Bruinstroop E, Singh BK, Yen PM. Nonalcoholic fatty liver disease and hypercholesterolemia: roles of thyroid hormones, metabolites, and agonists. Thyroid. 2019;29(9):1173\u201391. https:\/\/doi.org\/10.1089\/thy.2018.0664.","journal-title":"Thyroid"},{"issue":"2","key":"1484_CR26","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.atherosclerosis.2013.07.056","volume":"230","author":"R Taub","year":"2013","unstructured":"Taub R, Chiang E, Chabot-Blanchet M, et al. Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-\u03b2 agonist. Atherosclerosis. 2013;230(2):373\u201380. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2013.07.056.","journal-title":"Atherosclerosis"},{"issue":"10213","key":"1484_CR27","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","volume":"394","author":"SA Harrison","year":"2019","unstructured":"Harrison SA, Bashir MR, Guy CD, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019;394(10213):2012\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(19)32517-6.\u00a0","journal-title":"Lancet"},{"issue":"4","key":"1484_CR28","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/hep4.1657","volume":"5","author":"SA Harrison","year":"2021","unstructured":"Harrison SA, Bashir M, Moussa SE, et al. Effects of resmetirom on noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with NASH. Hepatol Commun. 2021;5(4):573\u201388. https:\/\/doi.org\/10.1002\/hep4.1657.\u00a0","journal-title":"Hepatol Commun"},{"key":"1484_CR29","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.2147\/DDDT.S315724","volume":"15","author":"JM Fraile","year":"2021","unstructured":"Fraile JM, Palliyil S, Barelle C, Porter AJ, Kovaleva M. Non-alcoholic steatohepatitis (NASH) - a review of a crowded clinical landscape, driven by a complex disease. Drug Des Devel Ther. 2021;15:3997\u20134009. https:\/\/doi.org\/10.2147\/DDDT.S315724.\u00a0","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"1484_CR30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/apt.17734","volume":"59","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Ratziu V, Anstee QM, et al. Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 2024;59(1):51\u201363. https:\/\/doi.org\/10.1111\/apt.17734.\u00a0","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"1484_CR31","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","volume":"29","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Taub R, Neff GW, et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2023;29(11):2919\u201328. https:\/\/doi.org\/10.1038\/s41591-023-02603-1.\u00a0","journal-title":"Nat Med"},{"issue":"6","key":"1484_CR32","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390(6):497\u2013509. https:\/\/doi.org\/10.1056\/NEJMoa2309000.","journal-title":"N Engl J Med"},{"issue":"1","key":"1484_CR33","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s43162-025-00468-z","volume":"37","author":"IJ Ogieuhi","year":"2025","unstructured":"Ogieuhi IJ, Olatunji G, Kokori E, et al. Resmetirom in the management of metabolic associated steatohepatitis (MASH): a review of efficacy and safety data from clinical trials. Egypt J Intern Med. 2025;37(1):78. https:\/\/doi.org\/10.1186\/s43162-025-00468-z.","journal-title":"Egypt J Intern Med"},{"key":"1484_CR34","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/1475-2840-11-130","volume":"11","author":"A Goto","year":"2012","unstructured":"Goto A, Morita A, Goto M, et al. Associations of sex hormone-binding globulin and testosterone with diabetes among men and women (the Saku Diabetes study): a case control study. Cardiovasc Diabetol. 2012;11:130. https:\/\/doi.org\/10.1186\/1475-2840-11-130.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1484_CR35","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1210\/jc.2004-0422","volume":"90","author":"W de Ronde","year":"2005","unstructured":"de Ronde W, van der Schouw YT, Muller M, et al. Associations of sex-hormone-binding globulin (SHBG) with non-SHBG-bound levels of testosterone and estradiol in independently living men. J Clin Endocrinol Metab. 2005;90(1):157\u201362. https:\/\/doi.org\/10.1210\/jc.2004-0422.\u00a0","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1484_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-022-04562-1","volume":"79","author":"N Narinx","year":"2022","unstructured":"Narinx N, David K, Walravens J, et al. Role of sex hormone-binding globulin in the free hormone hypothesis and the relevance of free testosterone in androgen physiology. Cell Mol Life Sci. 2022;79(11):543. https:\/\/doi.org\/10.1007\/s00018-022-04562-1.\u00a0","journal-title":"Cell Mol Life Sci"},{"issue":"7","key":"1484_CR37","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1210\/jc.2015-4106","volume":"101","author":"L Antonio","year":"2016","unstructured":"Antonio L, Wu FC, O\u2019Neill TW, et al. Low free testosterone is associated with hypogonadal signs and symptoms in men with normal total testosterone. J Clin Endocrinol Metab. 2016;101(7):2647\u201357. https:\/\/doi.org\/10.1210\/jc.2015-4106.\u00a0","journal-title":"J Clin Endocrinol Metab"},{"issue":"17","key":"1484_CR38","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJMc2402905","volume":"390","author":"A Sabet","year":"2024","unstructured":"Sabet A. A phase 3 trial of Resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390(17):1632. https:\/\/doi.org\/10.1056\/NEJMc2402905.","journal-title":"N Engl J Med"},{"issue":"9821","key":"1484_CR39","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/s0140-6736(11)60276-6","volume":"379","author":"DS Cooper","year":"2012","unstructured":"Cooper DS, Biondi B. Subclinical thyroid disease. Lancet. 2012;379(9821):1142\u201354. https:\/\/doi.org\/10.1016\/s0140-6736(11)60276-6.","journal-title":"Lancet"},{"key":"1484_CR40","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvad096","author":"S Odawara","year":"2023","unstructured":"Odawara S, Shimbo T, Yamauchi T, Kobayashi D. Association of low-normal free T4 levels with future major depression development. J Endocr Soc. 2023. https:\/\/doi.org\/10.1210\/jendso\/bvad096.","journal-title":"J Endocr Soc"},{"issue":"5","key":"1484_CR41","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1007\/s12325-021-01690-1","volume":"38","author":"A Lonardo","year":"2021","unstructured":"Lonardo A, Arab JP, Arrese M. Perspectives on precision medicine approaches to NAFLD diagnosis and management. Adv Ther. 2021;38(5):2130\u201358. https:\/\/doi.org\/10.1007\/s12325-021-01690-1.\u00a0","journal-title":"Adv Ther"},{"issue":"3","key":"1484_CR42","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jhep.2020.04.003","volume":"73","author":"QM Anstee","year":"2020","unstructured":"Anstee QM, Darlay R, Cockell S, et al. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort\u2606. J Hepatol. 2020;73(3):505\u201315. https:\/\/doi.org\/10.1016\/j.jhep.2020.04.003.","journal-title":"J Hepatol"},{"issue":"12","key":"1484_CR43","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1111\/apt.15738","volume":"51","author":"B Carlsson","year":"2020","unstructured":"Carlsson B, Linden D, Brolen G, et al. Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2020;51(12):1305\u201320. https:\/\/doi.org\/10.1111\/apt.15738.\u00a0","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"1484_CR44","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","volume":"68","author":"M Eslam","year":"2018","unstructured":"Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol. 2018;68(2):268\u201379. https:\/\/doi.org\/10.1016\/j.jhep.2017.09.003.\u00a0","journal-title":"J Hepatol"},{"key":"1484_CR45","doi-asserted-by":"publisher","DOI":"10.1101\/2024.04.22.590608","author":"M Xia","year":"2024","unstructured":"Xia M, Varmazyad M, Palacin IP, et al. Comparison of wild-type and high-risk PNPLA3 variants in a human biomimetic liver microphysiology system for metabolic dysfunction-associated steatotic liver disease precision therapy. bioRxiv. 2024. https:\/\/doi.org\/10.1101\/2024.04.22.590608.\u00a0","journal-title":"bioRxiv."},{"key":"1484_CR46","unstructured":"Alkhouri N. Resmetirom effects on NASH with liver fibrosis in patients with NASH genetic risk alleles. Gastroenterol Hepatol. 2024;20."},{"issue":"1","key":"1484_CR47","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1124\/pr.115.011411","volume":"68","author":"JT Backman","year":"2016","unstructured":"Backman JT, Filppula AM, Niemi M, Neuvonen PJ. Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016;68(1):168\u2013241. https:\/\/doi.org\/10.1124\/pr.115.011411.","journal-title":"Pharmacol Rev"},{"issue":"4","key":"1484_CR48","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1111\/j.1742-7843.2010.00581.x","volume":"107","author":"A Kalliokoski","year":"2010","unstructured":"Kalliokoski A, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism and oral antidiabetic drugs. Basic Clin Pharmacol Toxicol. 2010;107(4):775\u201381. https:\/\/doi.org\/10.1111\/j.1742-7843.2010.00581.x.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"3","key":"1484_CR49","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","volume":"158","author":"A Kalliokoski","year":"2009","unstructured":"Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009;158(3):693\u2013705. https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00430.x.","journal-title":"Br J Pharmacol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01484-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01484-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01484-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:57:27Z","timestamp":1760774247000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01484-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1484"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01484-1","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,23]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}